أرسل هذا في رسالة قصيرة: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

 __   _      ___    __    __    _____     _____   
| || | ||   / _ \\  \ \\ / //  |  ___||  |__  //  
| '--' ||  | / \ ||  \ \/ //   | ||__      / //   
| .--. ||  | \_/ ||   \  //    | ||__     / //__  
|_|| |_||   \___//     \//     |_____||  /_____|| 
`-`  `-`    `---`       `      `-----`   `-----`